N/A
Completed N=8
Safety and Efficacy of Trastuzumab BS
Source: ClinicalTrials.gov NCT04181333 ↗Enrolled (actual)
8
Serious AEs
42.9%
Results posted
Apr 2026
Primary outcomePrimary: The Incidence of Adverse Drug Reactions (ADRs) — 4; 0 Participants
Summary
To confirm the safety and efficacy of this drug under the actual use
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Incidence of Adverse Drug Reactions (ADRs) |
4; 0 | — |
| SECONDARY Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
85.7 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug*
- Patients who receive this drug* for the first time after this drug* is launched * Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug
Exclusion Criteria
- not specified in this study
Data sourced from ClinicalTrials.gov (NCT04181333). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.